Jeffrey A. Rona - 23 Feb 2026 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role: CBFO
Signature: /s/ Jeffrey Rona
Issuer symbol: OVID
Transactions as of: 23 Feb 2026
Net transactions value: -$12,384
Form type: 4
Filing time: 02 Mar 2026, 16:30:09 UTC
Previous filing: 28 Feb 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rona Jeffrey A	CBFO	C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, NEW YORK	/s/ Jeffrey Rona	02 Mar 2026	0001311404

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OVID	Common Stock	Sale	$12,384	-8,541	-8.8%	$1.45	88,188	23 Feb 2026	Direct	F1, F2, F3
transaction	OVID	Common Stock	Award	$0	+68,125	+77%	$0.000000	156,313	26 Feb 2026	Direct	F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OVID	Employee Stock Option (Right to Buy)	Award	$0	+408,750		$0.000000	408,750	26 Feb 2026	Common Stock	408,750	$1.65	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	Includes 28,756 shares acquired under the Issuer's employee stock purchase plan.
F4	Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 20, 2027, subject to the Reporting Person's continuous service through each such vesting date.
F5	Each RSU represents a contingent right to receive one share of Common Stock.
F6	The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.